<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01405599</url>
  </required_header>
  <id_info>
    <org_study_id>NPJ5004-01/2011 (HEP)</org_study_id>
    <nct_id>NCT01405599</nct_id>
  </id_info>
  <brief_title>Evaluation of the Pharmacokinetics of Ulimorelin in Subjects With Hepatic Impairment and Healthy Subjects</brief_title>
  <official_title>Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ulimorelin in Subjects With Mild, Moderate and Severe Hepatic Impairment, in Comparison With Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the effect of hepatic impairment on the pharmacokinetics of ulimorelin after a&#xD;
      single intravenous (IV) dose in order to identify potential patients at risks in terms of&#xD;
      severity of hepatic dysfunction and to determine whether their dosage should be adjusted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of ulimorelin</measure>
    <time_frame>15, 30, 45, 60, 75, 90 mins, 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 h post-infusion</time_frame>
    <description>To evaluate the pharmacokinetics of ulimorelin in subjects with mild, moderate and severe hepatic impairment compared with subjects who have normal hepatic function following a single dose administration of ulimorelin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC of ulimorelin</measure>
    <time_frame>15, 30, 45, 60, 75, 90 mins, 2, 4, 8, 12, 16, 24, 36, 48, 60, 72, 96, 120 h post-infusion</time_frame>
    <description>To evaluate the pharmacokinetics of ulimorelin in subjects with mild, moderate and severe hepatic impairment compared with subjects who have normal hepatic function following a single dose administration of ulimorelin</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Digestive System Disorders</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTP class C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTP class B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTP class A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulimorelin</intervention_name>
    <description>Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Mild hepatic impairment</arm_group_label>
    <arm_group_label>Moderate hepatic impairment</arm_group_label>
    <arm_group_label>Severe hepatic impairment</arm_group_label>
    <other_name>TZP101</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main Criteria for Inclusion All Subjects:&#xD;
&#xD;
          -  Adult male or female subjects age 18 to 75 years (both inclusive)&#xD;
&#xD;
          -  Able to understand and willing to sign an informed consent form (ICF) and able to&#xD;
             comply with the study restrictions&#xD;
&#xD;
          -  Female subjects must be postmenopausal (for at least 1 year and confirmed by serum&#xD;
             follicle-stimulating hormone (FSH) at screening), surgically sterile, practicing true&#xD;
             abstinence and/or must be using adequate contraception for the duration of the study&#xD;
             (e.g. contraceptive implants, injectables, oral contraceptives, and intra-uterine&#xD;
             device and/or barrier methods (condom/occlusive cap with spermicidal&#xD;
             foam/gel/film/cream/suppository))&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test at screening and&#xD;
             Day -1&#xD;
&#xD;
          -  Weight ≥ 50 kg and ≤ 200 kg&#xD;
&#xD;
          -  Body mass index (BMI) ≤ 40.0 kg/m2, where BMI (kg/m2) = Body weight (kg)/Height2 (m2)&#xD;
             Inclusion Criteria Hepatic Impairment Subjects (in addition to the criteria for all&#xD;
             subjects):&#xD;
&#xD;
          -  Documented mild, moderate or severe hepatic impairment defined as either Child-Pugh A,&#xD;
             B or C at screening&#xD;
&#xD;
          -  Stable hepatic impairment, defined as no clinically significant change in disease&#xD;
             status within the last 30 days before screening, as documented by the subject's recent&#xD;
             medical history (e.g., no worsening of clinical signs of hepatic impairment and no&#xD;
             worsening of total bilirubin or prothrombin time by more than 50%)&#xD;
&#xD;
          -  Must be on a stable dose of medication and/or treatment regimen at least 2 weeks&#xD;
             before dosing of study medication&#xD;
&#xD;
          -  Subjects with a history of substance abuse may be enrolled provided that they have not&#xD;
             abused drugs or alcohol for at least 6 months preceding the study Inclusion Criteria&#xD;
             for Healthy Subjects (in addition to criteria for all subjects):&#xD;
&#xD;
          -  Subjects with normal hepatic function, and liver parameters within normal range unless&#xD;
             approved by the Sponsor's Medical Representative&#xD;
&#xD;
          -  Subjects not using prescription drugs or non-prescription drugs, including&#xD;
             over-the-counter medication, non-routine vitamins and herbal products within 3 weeks&#xD;
             prior to dosing of investigational product [use of oral contraceptives, diuretics,&#xD;
             noncardioselective beta-blockers, topically applied medication (eye-/nose-drops and&#xD;
             creams) and occasional use of metaclopramide, ibuprofen and paracetamol is permitted].&#xD;
             Use of any other medication has to be discussed and agreed before inclusion of the&#xD;
             subject with the Medical Monitor and the Sponsor's medical representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Criteria for Exclusion All Subjects:&#xD;
&#xD;
          -  Known or suspected allergy to the trial product or related products&#xD;
&#xD;
          -  History of multiple and/or severe allergies to drugs or foods or a history of severe&#xD;
             anaphylactic reaction&#xD;
&#xD;
          -  Participation in another investigational drug trial within 30 days prior to dosing (or&#xD;
             5 times the half life of the drug if longer)&#xD;
&#xD;
          -  Acute illness within 14 days prior to dosing unless mild in severity and approved by&#xD;
             the Investigator and Sponsor's medical representative&#xD;
&#xD;
          -  History of drug abuse or positive urine drug screen (if not due to concomitant&#xD;
             medication) at Screening and/or Day -1&#xD;
&#xD;
          -  Ingestion of alcohol and caffeine within 24 hours prior to dosing and for the duration&#xD;
             of the study&#xD;
&#xD;
          -  Donation of more than 450mL of blood / blood products in the 30 days prior to dosing,&#xD;
             and/or blood donation in the 30 days prior to dosing&#xD;
&#xD;
          -  Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies or HIV-1&#xD;
             antigen according to locally used diagnostic testing&#xD;
&#xD;
          -  Creatinine clearance &lt;50mL/minute, estimated using serum creatinine with the formula&#xD;
             [(140 - age in years) × weight in kg]/[(72 × serum creatinine in mg/dL) × 0.85 for&#xD;
             female subjects]&#xD;
&#xD;
          -  Consumption of Seville oranges, grapefruit or grapefruit juice, star fruit and exotic&#xD;
             fruits from 7 days prior to first dose of study medication and for entire duration of&#xD;
             the study&#xD;
&#xD;
          -  Clinically significant abnormal haematology, biochemistry, coagulation or urinalysis&#xD;
             screening tests, as judged by the Investigator other than the abnormal values expected&#xD;
             considering the underlying disease&#xD;
&#xD;
          -  Subject with any disease or condition which the Investigator feels would interfere&#xD;
             with the trial outcome or compliance except for conditions associated with hepatic&#xD;
             impairment in the group of subjects with compromised hepatic function&#xD;
&#xD;
          -  Uncontrolled treated/untreated hypertension (systolic blood pressure ≥ 160 mmHg and&#xD;
             /or diastolic blood pressure ≥ 105 mmHg)&#xD;
&#xD;
          -  Use of prescription or over-the-counter medication that is extensively bound to&#xD;
             α1-acid glycoprotein (AAG) which the Investigator or Sponsor feels would interfere&#xD;
             with the trial outcome&#xD;
&#xD;
          -  History of cancer (judged not to be in full remission) or presence of cancer (except&#xD;
             basal cell skin cancer or squamous cell skin cancer) as judged by the Investigator&#xD;
&#xD;
          -  Subject who has undergone liver transplantation&#xD;
&#xD;
          -  Not able or willing to refrain from smoking during the inpatient period&#xD;
&#xD;
          -  Any condition that would make the subject unsuitable for clinical trial participation&#xD;
             as judged by the Investigator&#xD;
&#xD;
        Exclusion Criteria Hepatic Impairment Subjects (in addition to criteria for all subjects):&#xD;
&#xD;
          -  Any medical or surgical conditions, excluding underlying liver disease, which may&#xD;
             significantly interfere with the pharmacokinetics of the study drug&#xD;
&#xD;
          -  Fluctuating or rapidly deteriorating hepatic function&#xD;
&#xD;
        Exclusion Criteria for Healthy Subjects (in addition to criteria for all subjects):&#xD;
&#xD;
          -  Subjects with clinically significant illness as judged by the Investigator&#xD;
&#xD;
          -  Exposure to more than three new chemical entities within 12 months prior to the first&#xD;
             dosing day&#xD;
&#xD;
          -  Known acute hepatitis with viral, alcoholic, toxic or autoimmunological aetiology&#xD;
             within the last 6 months. Positive result to the screening test for Hepatitis B&#xD;
             antigen or Hepatitis C antibodies according to locally used diagnostic testing&#xD;
&#xD;
          -  Strenuous exercise within 48 hours prior to dosing and for the duration of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Tomas, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norgine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava, nem.</name>
      <address>
        <city>Bratislava</city>
        <zip>83305</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>July 22, 2011</study_first_submitted>
  <study_first_submitted_qc>July 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2011</study_first_posted>
  <last_update_submitted>October 15, 2012</last_update_submitted>
  <last_update_submitted_qc>October 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ulimorelin</keyword>
  <keyword>Hepatic Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

